(813) 971-8080

7210 Wareham Drive, Tampa, FL 33647

commercial weight loss

Weight Watchers Reports Q1 2026 Results

May 7, 2026 According to management:  “We remain confident in our strategy to build the industry-leading weight health platform. Our focus is on executing high-impact initiatives that drive Clinical growth and stabilize our Behavioral business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “We made encouraging […]

Weight Watchers Reports Q1 2026 Results Read More »

Medifast Reports Q1 2026 Results

May 6, 2026 Medifast reports its first quarter 2026 results. According to management: “We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership advancement, and high field engagement. These are metrics that have historically been

Medifast Reports Q1 2026 Results Read More »

U.S. Weight Loss Market Now Worth $135 Billion – New Report

March 4, 2026 Marketdata LLC has released a new report: “The U.S. Weight Loss Market: Status Report & 2026 Forecast” This 108-page analysis tracks the current status of ALL weight loss market segments, 2025 performance, the latest dieting trends, 15 competitor profiles, with 27 tables and charts. Some findings: The total U.S. weight loss market

U.S. Weight Loss Market Now Worth $135 Billion – New Report Read More »

Weight Watchers Hires New International V.P.

Sept. 3, 2025 WW announced the appointment of Alejandro Bethlen as Executive Vice President, International, effective immediately. In this role, Bethlen will oversee WeightWatchers’ business outside of the United States, driving international growth and innovation across the Company’s global footprint. “Alejandro’s international experience and commercial leadership make him uniquely suited to advance our growth outside

Weight Watchers Hires New International V.P. Read More »

Novo Nordisk Obesity Drugs Sales Slow – Compounders Still Selling illegally

August 6, 2025 Sales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of U.S. tariffs, coupled with continued competition from compounded drugs sold illegally. Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and

Novo Nordisk Obesity Drugs Sales Slow – Compounders Still Selling illegally Read More »

Weight Watchers Expands Collaboration With Novo Nordisk

July 2, 2025 Weight Watchers announced an expanded collaboration with Novo Nordisk, which includes increased access to authentic, FDA-approved Wegovy® (semaglutide) injection through Weight Watchers Clinic. As part of the collaboration, Weight Watchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, which serves as the dispensing pharmacy for the

Weight Watchers Expands Collaboration With Novo Nordisk Read More »

Scroll to Top